Benzodiazepines: Risks and benefits. A reconsideration

  title={Benzodiazepines: Risks and benefits. A reconsideration},
  author={David S. Baldwin and Katherine J. Aitchison and Alan N. Bateson and H. Valerie Curran and Simon J C Davies and Brian E. Leonard and David J. Nutt and David Norman Dr Stephens and Sue J. Wilson},
  journal={Journal of Psychopharmacology},
  pages={967 - 971}
Over the last decade there have been further developments in our knowledge of the risks and benefits of benzodiazepines, and of the risks and benefits of alternatives to benzodiazepines. Representatives drawn from the Psychopharmacology Special Interest Group of the Royal College of Psychiatrists and the British Association for Psychopharmacology together examined these developments, and have provided this joint statement with recommendations for clinical practice. The working group was mindful… Expand
Benzodiazepines Dependence: Addiction to Legally Prescribed Substances
The undue use of benzodiazepines can lead to dependence of this substance, constituting a serious health problem, hard to manage therapeutically. Despite this finding, the prescription ofExpand
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
  • V. Starcevic
  • Psychology, Medicine
  • Expert review of neurotherapeutics
  • 2014
Treatment guidelines should acknowledge that BDZs can be used as first-line, long-term pharmacological treatment for panic disorder, generalized anxiety disorder and social anxiety disorder, and suggest that pharmacotherapy options for anxiety and related disorders should be reviewed. Expand
Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
  • K. Rickels, H. Moeller
  • Medicine
  • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2018
Results of a controlled trial as proposed will go a long way in providing clinicians missing information to guide them in the appropriate use of both BZs and ADs in anxiety disorders. Expand
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
It is concluded that little evidence exists outside the usual principles of drug withdrawal but there are some promising leads. Expand
Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice
A group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. Expand
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology.
The oppositional neuropharmacological interactions between chronic benzodiazepine use and antidepressant mechanism of action, which could result in reduced antidepressant efficacy and function in depression are discussed. Expand
Prescribing and Dispensing of Benzodiazepines
Despite substantial adverse effects from benzodiazepine use, these medicines are frequently prescribed and dispensed and some recommendations appear well accepted, and are best implemented if doctors and pharmacists work as a team. Expand
Clonazepam: Indications, Side Effects, and Potential for Nonmedical Use.
There is a need to find safer therapeutic alternatives for treating seizures and anxiety disorders and greater awareness of its frequent nonmedical use is also needed to achieve safer overall use of this medication. Expand
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.
To assist individuals with discontinuing long-term use of benzodiazepines, gradual withdrawal, psychological support and pharmacological intervention are recommended. Expand
The misuse of benzodiazepines among high-risk opioid users in Europe
  • 2015
Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. They are useful in the short-term treatment of anxiety and insomnia, and in managingExpand


Do Benzodiazepines Still Deserve a Major Role in The Treatment of Psychiatric Disorders? A Critical Reappraisal
A critical appraisal of the current use and role of BZDs in psychiatric disorders and their disadvantages is provided, with specific emphasis on anxiety and affective disorders, sleep disorders, alcohol withdrawal, violent and aggressive behaviours in psychoses, and neuroleptic-induced disorders. Expand
Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal.
  • A. Bateson
  • Medicine
  • Current pharmaceutical design
  • 2002
The molecular effects of long-term benzodiazepine exposure are reviewed and a model is presented that draws on results from a number of research groups working in this area. Expand
British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders
These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. Expand
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
These British Association for Psychopharmacology guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments. Expand
Substitution therapy for alcoholism: time for a reappraisal?
The time now seems right for reappraising the use of substitute prescribing for alcohol dependence, where existing therapies are only effective in a proportion of patients, and which has high morbidity and mortality. Expand
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Expand
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy
The recent review of the selective serotonin reuptake inhibitors (SSRIs) by the Committee on Safety of Medicines (CSM) and the Food and Drug Administration was occasioned by media concerns about theExpand
Randomised controlled trial of two brief interventions against long-term benzodiazepine use: outcome of intervention
Brief intervention, either in the form of the offer of a short consultation or a letter from the patient's GP, is effective in leading to reduced BZD intake without adverse consequences among long-term benzodiazepine (BZD) users. Expand
Benzodiazepine Dependence in Adverse Syndromes and Psychiatric Drugs eds P.M.Haddad
  • Serdar Dursun and Bill Deakin , Oxford university Press
  • 2004